CATL Shares Fall as Hungary Plant Faces Safety Halt 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
France Targets Shein, Temu With Fast-Fashion Fees 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Milei Threatens Falkland Oil Firms With Sanctions 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
(4) - EconoTimes)
Add as a preferred source on Google
WAYNE, Pa., March 06, 2018 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that, on March 5, 2018, the Compensation Committee of Aclaris’ Board of Directors granted 3 non-qualified stock option awards to purchase an aggregate of 8,900 shares of its common stock and 3 restricted stock unit awards covering an aggregate of 1,500 shares of its common stock to 3 new employees under the Aclaris 2017 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
The 2017 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
The options have an exercise price of $20.13 per share, which is equal to the closing price of Aclaris' common stock on March 5, 2018. Each option and restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of the shares on each of the first, second, third and fourth anniversaries of the recipient's start date, subject to each such employee's continued employment with Aclaris on such vesting dates. The options and restricted stock unit awards are subject to the terms and conditions of Aclaris' 2017 Inducement Plan, and the terms and conditions of a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. The Company focuses on market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is based in Wayne, Pennsylvania. More information can be found by visiting the Aclaris website at www.aclaristx.com.
Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
[email protected]
